Business ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Market Competition Clinical Research Market Trends Regulatory Affairs Market Approval Market Access Market Launch Market Impact Regulatory Approval

Lilly’s Foundayo Pill Significantly Improves Sleep Apnea in Late‑Stage Trials

Lilly plans a year‑end FDA filing that could widen non‑PAP treatment options for adults who are overweight or have obesity.

Two High‑Profile Heart Trials Fail to Cut Events Despite Big Biomarker Drops

Lilly’s Retatrutide Outperforms Ozempic in Late‑Stage Diabetes Trial

Retatrutide Drives Record Weight Loss in Type 2 Diabetes, Company Moves Toward U.S. Filing

uniQure Shares Plummet After AMT-130 Misses Pre-Specified Statistical Goal

Lawsuits Over GLP‑1 Drugs Mount After Reports of Rare Sudden Vision Loss

Stanford’s 37,000‑Agent 'Virtual Biotech' Finds Trial‑Success Signal and Designs Lung‑Cancer Therapy

Definium’s LSD-Based Therapy Posts Third Positive Phase 3 Result in GAD

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

Anvisa Approves Two EMS Liraglutide Generics

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Novo Nordisk’s Semaglutide Eases Childhood Obesity as Heart-Drug Trials Are Halted

Wegovy Tablet Arrives in Germany as Prescription Weight‑Loss Option

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

Anvisa Registers Yluméc, EMS Semaglutide Pen for Type 2 Diabetes

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

Moderna and Merck Report First Phase III Win for an mRNA Cancer Vaccine